Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to figure out what effects (good or bad) the investigational
drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated
adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute Pasi A. Janne, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Genentech, Inc. Massachusetts General Hospital